Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster Immunological Response to RBD‑mRNA COVID‑19 Vaccine DS-5670
jRCT1031240457Active, not recruiting
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of DS-5670a in coronavirus disease 2019 (COVID-19), sponsored by none. Primary endpoint: SARS-CoV-2 neutralizing antibody titer against Omicron JN-1. Started Nov 2024; status: active, not recruiting.
02
Drugs
DS-5670a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1031240457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240457.